[L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D010300:Parkinson Disease / Q000188:drug therapy*
D004338:Drug Combinations; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
L-Dopa-Therapie des Parkinson-Syndroms. Vergleich von reinem L-Dopa und dem Kombinationspräparat L-Dopa + Decarboxylasehemmer.